Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue
Open Access
- 17 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 108 (6) , 945-959
Abstract
Polycystic ovary syndrome is a complicated hormonal and metabolic disorder. The exact pathogenesis of polycystic ovary syndrome is not clear thus far. Inflammation is involved in the progression of polycystic ovary syndrome. In addition, brown adipose tissue activity is impaired in polycystic ovary syndrome. Interestingly, glucagon-like peptide-1 receptor agonists have been reported to alleviate inflammation and promote browning of white adipose tissue. In this study, the effects of glucagon-like peptide-1 receptor agonists on polycystic ovary syndrome mice were explored. Mice were randomly assigned into four groups: control, dehydroepiandrosterone, dehydroepiandrosterone + liraglutide, and dehydroepiandrosterone + semaglutide. Relative indexes were measured after glucagon-like peptide-1 receptor agonist intervention. Glucose metabolism in polycystic ovary syndrome mice was ameliorated by glucagon-like peptide-1 receptor agonists, while the reproductive endocrine disorder of polycystic ovary syndrome mice was partially reversed. The messenger ribonucleic acid levels of steroidogenic enzymes and the expression of inflammatory mediators in serum and ovaries of polycystic ovary syndrome mice were improved. Furthermore, toll-like receptor 4 and phosphorylation of nuclear factor-kappa B protein levels were decreased by glucagon-like peptide-1 receptor agonists in ovary. Notably, after glucagon-like peptide-1 receptor agonist intervention, the expression of brown adipose tissue marker levels was considerably raised in the white adipose tissue of polycystic ovary syndrome mice. In conclusion, the hyperinsulinemia and hyperandrogenemia of polycystic ovary syndrome mice were alleviated by glucagon-like peptide-1 receptor agonist intervention, which was associated with mitigating inflammation and stimulating adipose tissue browning.Keywords
Funding Information
- National Natural Science Foundation of China (81870594, 82170879)
- Cross-Institute Research Fund of Shanghai Jiao Tong University (YG2019GD05)
This publication has 70 references indexed in Scilit:
- Fasting and post‐prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndromeClinical Endocrinology, 2014
- Adipose tissue browning and metabolic healthNature Reviews Endocrinology, 2013
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone ActionCell Metabolism, 2013
- Acute exercise induces a phenotypic switch in adipose tissue macrophage polarization in diet‐induced obese ratsObesity, 2013
- Performing Vaginal Lavage, Crystal Violet Staining, and Vaginal Cytological Evaluation for Mouse Estrous Cycle Staging IdentificationJournal of Visualized Experiments, 2012
- Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic riskFertility and Sterility, 2012
- CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 StatusDiabetes, 2012
- Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunctionSteroids, 2012
- Polycystic ovary syndrome: etiology, pathogenesis and diagnosisNature Reviews Endocrinology, 2011
- An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndromeGynecological Endocrinology, 2010